PPAR‐γ ligation alone and in combination with either RXR agonist like LG100268 or a retinoic acid receptor agonist like all‐trans‐retinoic acid, has been shown to inhibit growth and enhance differentiating in myeloid cells (U937 and HL‐60) lymphoid cells (Su‐DHL, Sup‐M2, Ramos, Raji, Hodgkin's cell lines) and primary chronic lymphocytic leukaemia cells, by activating the transcriptional activity of target genes controlling apoptosis and differentiation in leukaemias.123. The gene discussed is PPARG; the disease is leukemia.